Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy

Jurgita Sauvageot, Jonathan Ira Epstein

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Although, in general, immunoperoxidase staining for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) cannot distinguish between benign and malignant prostatic epithelium, immunoreactivity of these antigens may be helpful in predicting prognosis of prostate cancer. The purpose of this study was to evaluate intensity and extent of immunoperoxidase staining for PSA and PSAP as a prognostic tool in prostate adenocarcinomas. METHODS. We studied radical prostatectomy specimens from 68 patients with the following stages: organ-confined, 34.3%; focal capsular penetration, 38.8%; established capsular penetration, 25.3%; and seminal vesicle invasion, 1.6%. Ninety-one percent of cases were Gleason score 5-7. The mean follow-up for those men without progression was 8.9 years, compared to 3.5 years for those with progression. Progression was defined as an elevated postoperative serum PSA level (>0.2 ng/ml). Intensity of PSA and PSAP staining was recorded and based on a scale of 0-3 (0, no staining; 1, weak; 2, moderate; 3, intense). Extent was quantitated on a scale of 0-4 (0, 0-5% staining; 1, 6-35%; 2, 36-65%; 3, 65-95%; 4, 95-100%). A score (0-12) was computed by multiplying intensity and extent of the stain in the tumor area. RESULTS AND CONCLUSIONS. Intensity and extent of PSA and PSAP immunoreactivity did not predict progression in adenocarcinomas of the prostate following radical prostatectomy.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalProstate
Volume34
Issue number1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostate
Adenocarcinoma
Acid Phosphatase
Staining and Labeling
Neoplasm Grading
Seminal Vesicles
prostatic acid phosphatase
Prostatic Neoplasms
Coloring Agents
Epithelium
Antigens
Serum
Neoplasms

Keywords

  • Immunohistochemistry
  • Prostate adenocarcinoma
  • PSA
  • PSAP
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

@article{2cb172ef42eb4dd1b09fbfac1d5fcfff,
title = "Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy",
abstract = "BACKGROUND. Although, in general, immunoperoxidase staining for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) cannot distinguish between benign and malignant prostatic epithelium, immunoreactivity of these antigens may be helpful in predicting prognosis of prostate cancer. The purpose of this study was to evaluate intensity and extent of immunoperoxidase staining for PSA and PSAP as a prognostic tool in prostate adenocarcinomas. METHODS. We studied radical prostatectomy specimens from 68 patients with the following stages: organ-confined, 34.3{\%}; focal capsular penetration, 38.8{\%}; established capsular penetration, 25.3{\%}; and seminal vesicle invasion, 1.6{\%}. Ninety-one percent of cases were Gleason score 5-7. The mean follow-up for those men without progression was 8.9 years, compared to 3.5 years for those with progression. Progression was defined as an elevated postoperative serum PSA level (>0.2 ng/ml). Intensity of PSA and PSAP staining was recorded and based on a scale of 0-3 (0, no staining; 1, weak; 2, moderate; 3, intense). Extent was quantitated on a scale of 0-4 (0, 0-5{\%} staining; 1, 6-35{\%}; 2, 36-65{\%}; 3, 65-95{\%}; 4, 95-100{\%}). A score (0-12) was computed by multiplying intensity and extent of the stain in the tumor area. RESULTS AND CONCLUSIONS. Intensity and extent of PSA and PSAP immunoreactivity did not predict progression in adenocarcinomas of the prostate following radical prostatectomy.",
keywords = "Immunohistochemistry, Prostate adenocarcinoma, PSA, PSAP, Radical prostatectomy",
author = "Jurgita Sauvageot and Epstein, {Jonathan Ira}",
year = "1998",
month = "1",
day = "1",
doi = "10.1002/(SICI)1097-0045(19980101)34:1<29::AID-PROS4>3.0.CO;2-F",
language = "English (US)",
volume = "34",
pages = "29--33",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate

T2 - Relation to progression following radical prostatectomy

AU - Sauvageot, Jurgita

AU - Epstein, Jonathan Ira

PY - 1998/1/1

Y1 - 1998/1/1

N2 - BACKGROUND. Although, in general, immunoperoxidase staining for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) cannot distinguish between benign and malignant prostatic epithelium, immunoreactivity of these antigens may be helpful in predicting prognosis of prostate cancer. The purpose of this study was to evaluate intensity and extent of immunoperoxidase staining for PSA and PSAP as a prognostic tool in prostate adenocarcinomas. METHODS. We studied radical prostatectomy specimens from 68 patients with the following stages: organ-confined, 34.3%; focal capsular penetration, 38.8%; established capsular penetration, 25.3%; and seminal vesicle invasion, 1.6%. Ninety-one percent of cases were Gleason score 5-7. The mean follow-up for those men without progression was 8.9 years, compared to 3.5 years for those with progression. Progression was defined as an elevated postoperative serum PSA level (>0.2 ng/ml). Intensity of PSA and PSAP staining was recorded and based on a scale of 0-3 (0, no staining; 1, weak; 2, moderate; 3, intense). Extent was quantitated on a scale of 0-4 (0, 0-5% staining; 1, 6-35%; 2, 36-65%; 3, 65-95%; 4, 95-100%). A score (0-12) was computed by multiplying intensity and extent of the stain in the tumor area. RESULTS AND CONCLUSIONS. Intensity and extent of PSA and PSAP immunoreactivity did not predict progression in adenocarcinomas of the prostate following radical prostatectomy.

AB - BACKGROUND. Although, in general, immunoperoxidase staining for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) cannot distinguish between benign and malignant prostatic epithelium, immunoreactivity of these antigens may be helpful in predicting prognosis of prostate cancer. The purpose of this study was to evaluate intensity and extent of immunoperoxidase staining for PSA and PSAP as a prognostic tool in prostate adenocarcinomas. METHODS. We studied radical prostatectomy specimens from 68 patients with the following stages: organ-confined, 34.3%; focal capsular penetration, 38.8%; established capsular penetration, 25.3%; and seminal vesicle invasion, 1.6%. Ninety-one percent of cases were Gleason score 5-7. The mean follow-up for those men without progression was 8.9 years, compared to 3.5 years for those with progression. Progression was defined as an elevated postoperative serum PSA level (>0.2 ng/ml). Intensity of PSA and PSAP staining was recorded and based on a scale of 0-3 (0, no staining; 1, weak; 2, moderate; 3, intense). Extent was quantitated on a scale of 0-4 (0, 0-5% staining; 1, 6-35%; 2, 36-65%; 3, 65-95%; 4, 95-100%). A score (0-12) was computed by multiplying intensity and extent of the stain in the tumor area. RESULTS AND CONCLUSIONS. Intensity and extent of PSA and PSAP immunoreactivity did not predict progression in adenocarcinomas of the prostate following radical prostatectomy.

KW - Immunohistochemistry

KW - Prostate adenocarcinoma

KW - PSA

KW - PSAP

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0031983710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031983710&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19980101)34:1<29::AID-PROS4>3.0.CO;2-F

DO - 10.1002/(SICI)1097-0045(19980101)34:1<29::AID-PROS4>3.0.CO;2-F

M3 - Article

C2 - 9428385

AN - SCOPUS:0031983710

VL - 34

SP - 29

EP - 33

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -